India Ratings expects domestic pharma growth of ~10% in FY27, though US market weakness and rising input/logistics costs may weigh…
Natco Pharma shares fell 6% as Q1 profit dropped 57% on lower lenalidomide revenue; firm set a Rs 1.50 dividend.…
India’s pharma July sales rise 12.1% on higher prices, new launches and rising GLP-1 demand.
India’s IT slowdown has created an unlikely outperformer. A niche business model, sticky clients and AI-led transformation are driving growth,…
Nifty’s short-covering rally may extend as Metal and Healthcare flash bullish setups; watch Torrent Pharma, Apollo and key levels Monday.
Trump’s threat of 200% tariffs on generics may well encourage Indian firms to invest further in the US with focus…
Torrent Pharma Q1 profit rose 3% to Rs 566 crore as revenue jumped 55% and EBITDA climbed 61%; see key…
Cipla and Dr. Reddy’s entered FY27 on different trajectories. While Cipla posted record quarterly revenue backed by respiratory growth, Dr.…
Biocon wins Health Canada approval for Yesintek autoinjector, expanding autoimmune biosimilar options in Canada. Read more.
A parliamentary panel urges tighter regulation on non-scheduled medicines in India, highlighting major price control gaps and widespread profiteering in…
Nifty eyes an expiry bounce as FIIs stay heavily short and pharma, financials test key supports; watch 25,300 breaks for…
Bernstein says Trump’s proposed tariffs on generic medicines may create near-term uncertainty, but large Indian drugmakers remain well positioned for…
Dr Reddy’s hits a 52-week low after weak Q1 earnings, Semaglutide API issues and Middle East costs trigger target cuts;…
Move may unravel given US consumers’ reliance on India’s low-cost generics, analysts feel
Dr Reddy’s Q1FY27 net profit fell 69% YoY to Rs 443.5 crore, hit by Rs 239.7 crore semaglutide API provisions;…
Since higher cost of operations is a major deterrent at the moment, Indian pharma companies see the likely implications in…
Track pharma stocks as Trump’s phased US tariff plan hits sentiment, though analysts say India’s cost edge may cushion generic…
Track Emcure Pharma as Motilal Oswal starts Buy with a ₹2,260 target, citing 27% upside and multi-engine growth across chronic,…